| 注册
首页|期刊导航|中国全科医学|磷脂酰肌醇3-激酶/哺乳动物雷帕霉素靶蛋白抑制剂在乳腺癌治疗中的研究进展

磷脂酰肌醇3-激酶/哺乳动物雷帕霉素靶蛋白抑制剂在乳腺癌治疗中的研究进展

张晟 张霄蓓 张瑾

中国全科医学2012,Vol.15Issue(24):2749-2754,6.
中国全科医学2012,Vol.15Issue(24):2749-2754,6.DOI:10.3969/j.issn.1007-9572.2012.08.087

磷脂酰肌醇3-激酶/哺乳动物雷帕霉素靶蛋白抑制剂在乳腺癌治疗中的研究进展

Inhibitor in Breast CancerLatest Research Progress of PI3K/mTOR

张晟 1张霄蓓 1张瑾1

作者信息

  • 1. 300060,天津市,天津医科大学附属肿瘤医院天津乳腺癌防治研究中心乳腺三科,教育部乳腺癌防治重点实验室,天津市,天津市肿瘤防治重点实验室
  • 折叠

摘要

Abstract

The PI3K/AKT/mTOR signaling pathway is involved in the inhibition of tumor cell apoptosis, the promo-tion of cell survival, cell cycle regulation, tumor angiogenesis, invasion and metastasis and therefore plays an important role in tumorigenesis, tumor growth, tumor treatment and patients' prognosis. Recent studies showed this signaling pathway is closely related to breast cancer, making it a new therapeutic target and a hotspot in breast cancer research. Pre - clinical studies have confirmed that PI3K inhibitors and mTOR inhibitors achieve anticancer effects by targeting different targets of the PI3K/AKT/mT0R signaling pathway. Among the PI3K inhibitors, some medicines only target PI3K, whereas others target both PI3K and mTOR. Currently, researchers tend to focus on molecular targets based on different PI3K subtypes to achieve more targeted and specific inhibition of the PI3K pathway. However, the clinical efficacy and efficiency of these inhibitors need to be further studied. The mTOR inhibitors target mTORCl and have been become relatively well - developed targeted therapies for the PI3K/AKT/ mTOR pathway. Rapamycin derivatives have been studied in phase Ⅱ/Ⅲ clinical trials in breast cancer, and these derivatives a-chieved positive results in the treatment of metastatic breast cancer when combined with endocrine therapy or Her - 2 - targeted therapies.

关键词

乳腺肿瘤/1-磷脂酰肌醇3-激酶/哺乳动物雷帕霉素靶蛋白

Key words

Breast neoplasms/ 1 - phosphatidylinositol 3 - kinase/ Mammalian target of rapamycin

分类

医药卫生

引用本文复制引用

张晟,张霄蓓,张瑾..磷脂酰肌醇3-激酶/哺乳动物雷帕霉素靶蛋白抑制剂在乳腺癌治疗中的研究进展[J].中国全科医学,2012,15(24):2749-2754,6.

基金项目

科技部国际合作重大项目(2010DFB30270) (2010DFB30270)

中国全科医学

OA北大核心CSCDCSTPCD

1007-9572

访问量0
|
下载量0
段落导航相关论文